VBIO Latest Press Releases

-- October 28, 2026 --

Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation ACCESS Newswire 7:45 AM

-- October 26, 2026 --

Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options ACCESS Newswire 8:00 AM

-- October 21, 2026 --

Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value ACCESS Newswire 8:00 AM

-- October 15, 2026 --

Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone ACCESS Newswire 8:00 AM

-- October 14, 2026 --

With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge ACCESS Newswire 8:15 AM

-- October 9, 2026 --

Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers ACCESS Newswire 7:47 AM

-- October 5, 2026 --

New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod ACCESS Newswire 8:30 AM

-- September 30, 2026 --

3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours Globe Newswire 10:22 AM

Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity ACCESS Newswire 7:45 AM

-- September 23, 2026 --

Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions ACCESS Newswire 8:00 AM

-- September 22, 2026 --

Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule ACCESS Newswire 8:00 AM

-- September 1, 2026 --

Valion Bio Announces Changes to Management and Board of Directors ACCESS Newswire 8:05 AM

-- August 27, 2026 --

Valion Bio Announces Reverse Stock Split ACCESS Newswire 8:30 AM

-- August 13, 2026 --

Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase ACCESS Newswire 10:00 AM

-- August 12, 2026 --

Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury ACCESS Newswire 9:31 AM

-- July 22, 2026 --

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway PRNewswire 7:45 AM

-- July 20, 2026 --

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market PRNewswire 1:29 PM

-- July 14, 2026 --

Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion PRNewswire 7:45 AM

-- June 25, 2026 --

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS PRNewswire 7:45 AM

-- June 11, 2026 --

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures PRNewswire 7:45 AM

Market Data Delayed 15 Minutes